Souhaitez-vous accéder aux communiqués récents ?

THE COMPANY EXPECTS TO RELEASE TOPLINE RESULTS FOR SKNJCT-003 PHASE 2 CLINICAL TRIAL BEFORE THE END OF Q1 2026 AND REQUEST END-OF-PHASE 2 (EOP2) WITH THE FOOD AND DRUG ADMINISTRATION (FDA) IN H1 2026 ...

TORONTO, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research...

Los Angeles, CA, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Claire’s Place Foundation, a nonprofit organization providing support to children and families affected by cystic fibrosis (CF), closes out an...

Dyadic Applied BioSolutions Establishes Commercial Partnership to Accelerate Adoption of Dyadic’s Recombinant Growth Factors and Media Proteins

 IND submitted for ABP-102/CT-P72, a HER2 × CD3 T cell engager, with preclinical studies demonstrating enhanced HER2-high tumor selectivity and a favorable safety profile ABP-102/CT-P72 represents...

Pune, India, Dec. 15, 2025 (GLOBE NEWSWIRE) -- The QKS Group SPARK Matrix™ provides competitive analysis & ranking of the leading NDR vendors. InvGate, with its comprehensive InvGate Asset...

Company is on track to file the Phase 3 protocol in the fourth quarter of 2025 SAN FRANCISCO, Dec. 15, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the Office of...

Soverli launches a sovereign OS layer for any commercial smartphone — independent of Android and iOS, yet fully compatible and requirin

VANCOUVER, British Columbia, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Skeena Resources Limited (TSX: SKE, NYSE: SKE) (“Skeena Gold & Silver”, “Skeena” or the “Company”) is pleased to announce that the...

Landmark results could pave the way for miv-cel to become the first FDA-approved CAR T-cell therapy for autoimmune disease; Company on track to submit BLA for stiff person syndrome in 1H 2026  ...